• 1
    E. Alcamo, J.P. Mizgerd, B.H. Horwitz, R. Bronson, A.A. Beg, M. Scott, C.M. Doerschuk, R.O. Hynes and D. Baltimore, Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for kappa B in leukocyte recruitment, J Immunol 167 (2001), 15921600.
  • 2
    M. Alkhalaf and S. Jaffal, Potent antiproliferative effects of resveratrol on human osteosarcoma SJSA1 cells: novel cellular mechanisms involving the ERKs/p53 cascade, Free Radic Biol Med 41 (2006), 318325.
  • 3
    R.H. Arch, R.W. Gedrich and C.B. Thompson, Tumor necrosis factor receptor-associated factors (TRAFs)—a family of adapter proteins that regulates life and death, Genes Dev 12 (1998), 28212830.
  • 4
    A. Arlt, A. Gehrz, S. Muerkoster, J. Vorndamm, M.L. Kruse, U.R. Folsch and H. Schafer, Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death, Oncogene 22 (2003), 32433251.
  • 5
    N. Auphan, J.A. DiDonato, C. Rosette, A. Helmberg and M. Karin, Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis, Science 270 (1995), 286290.
  • 6
    P.A. Baeuerle and T. Henkel, Function and activation of NF-kappa B in the immune system, Annu Rev Immunol 12 (1994), 141179.
  • 7
    A.S. Baldwin, Jr., The NF-kappa B and I kappa B proteins: new discoveries and insights, Annu Rev Immunol 14 (1996), 649683.
  • 8
    C.F. Barroga, J.K. Stevenson, E.M. Schwarz and I.M. Verma, Constitutive phosphorylation of I kappa B alpha by casein kinase II, Proc Natl Acad Sci USA 92 (1995), 76377641.
  • 9
    A.A. Beg, W.C. Sha, R.T. Bronson, S. Ghosh and D. Baltimore, Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B, Nature 376 (1995), 167170.
  • 10
    M. Bentires-Alj, V. Barbu, M. Fillet, A. Chariot, B. Relic, N. Jacobs, J. Gielen, M.P. Merville and V. Bours, NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells, Oncogene 22 (2003), 9097.
  • 11
    D. Bernard, D. Monte, B. Vandenbunder and C. Abbadie, The c-Rel transcription factor can both induce and inhibit apoptosis in the same cells via the upregulation of MnSOD, Oncogene 21 (2002), 43924402.
  • 12
    K.P. Bhat and J.M. Pezzuto, Cancer chemopreventive activity of resveratrol, Ann N Y Acad Sci 957 (2002), 210229.
  • 13
    X. Bian, L.M. McAllister-Lucas, F. Shao, K.R. Schumacher, Z. Feng, A.G. Porter, V.P. Castle and A.W. Opipari Jr., NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells, J Biol Chem 276 (2001), 4892148929.
  • 14
    J. Bohuslav, L.F. Chen, H. Kwon, Y. Mu and W.C. Greene, p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1, J Biol Chem 279 (2004), 2611526125.
  • 15
    M. Bond, R.P. Fabunmi, A.H. Baker and A.C. Newby, Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B, FEBS Lett 435 (1998), 2934.
  • 16
    M.A. Brach, R. Hass, M.L. Sherman, H. Gunji, R. Weichselbaum and D. Kufe, Ionizing radiation induces expression and binding activity of the nuclear factor kappa B, J Clin Invest 88 (1991), 691695.
  • 17
    T.R. Brummelkamp, S.M. Nijman, A.M. Dirac and R. Bernards, Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB, Nature 424 (2003), 797801.
  • 18
    J.R. Burke, M.A. Pattoli, K.R. Gregor, P.J. Brassil, J.F. MacMaster, K.W. McIntyre, X. Yang, V.S. Iotzova, W. Clarke, J. Strnad, Y. Qiu and F.C. Zusi, BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice, J Biol Chem 278 (2003), 14501456.
  • 19
    J.H. Caamano, P. Perez, S.A. Lira and R. Bravo, Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo, Mol. Cell. Biol. 16 (1996), 13421348.
  • 20
    A.C. Castro, L.C. Dang, F. Soucy, L. Grenier, H. Mazdiyasni, M. Hottelet, L. Parent, C. Pien, V. Palombella and J. Adams, Novel IKK inhibitors: beta-carbolines, Bioorg Med Chem Lett 13 (2003), 24192422.
  • 21
    M. Cavo, Proteasome inhibitor bortezomib for the treatment of multiple myeloma, Leukemia 20 (2006), 13.
  • 22
    T.C. Chang, M.W. Hung, S.Y. Jiang, J.T. Chu, L.L. Chu and L.C. Tsai, Dexamethasone suppresses apoptosis in a human gastric cancer cell line through modulation of bcl-x gene expression, FEBS Lett 415 (1997), 1115.
  • 23
    D. Chendil, R.S. Ranga, D. Meigooni, S. Sathishkumar and M.M. Ahmed, Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3, Oncogene 23 (2004), 15991607.
  • 24
    D. Chilov, E. Kukk, S. Taira, M. Jeltsch, J. Kaukonen, A. Palotie, V. Joukov and K. Alitalo, Genomic organization of human and mouse genes for vascular endothelial growth factor C, J Biol Chem 272 (1997), 2517625183.
  • 25
    S. Cho, Y. Urata, T. Iida, S. Goto, M. Yamaguchi, K. Sumikawa and T. Kondo, Glutathione downregulates the phosphorylation of I kappa B: autoloop regulation of the NF-kappa B-mediated expression of NF-kappa B subunits by TNF-alpha in mouse vascular endothelial cells, Biochem Biophys Res Commun 253 (1998), 104108.
  • 26
    K.S. Chun, Y.S. Keum, S.S. Han, Y.S. Song, S.H. Kim and Y.J. Surh, Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation, Carcinogenesis 24 (2003), 15151524.
  • 27
    J.C. Cusack, Jr., R. Liu, M. Houston, K. Abendroth, P.J. Elliott, J. Adams and A.S. Baldwin, Jr., Enhanced chemosensi- tivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition, Cancer Res 61 (2001), 35353540.
  • 28
    F. D'Acquisto, A. Ialenti, A. Ianaro, R. Di Vaio and R. Carnuccio, Local administration of transcription factor decoy oligonucleotides to nuclear factor-kappaB prevents carrageenin-induced inflammation in rat hind paw, Gene Ther 7 (2000), 17311737.
  • 29
    R. Dechend, F. Hirano, K. Lehmann, V. Heissmeyer, S. Ansieau, F.G. Wulczyn, C. Scheidereit and A. Leutz, The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators, Oncogene 18 (1999), 33163323.
  • 30
    Q.L. Deveraux, N. Roy, H.R. Stennicke, T. Van Arsdale, Q. Zhou, S.M. Srinivasula, E.S. Alnemri, G.S. Salvesen and J.C. Reed, IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases, Embo J 17 (1998), 22152223.
  • 31
    Q.L. Deveraux, R. Takahashi, G.S. Salvesen and J.C. Reed, X-linked IAP is a direct inhibitor of cell-death proteases, Nature 388 (1997), 300304.
  • 32
    T.S. Doi, M.W. Marino, T. Takahashi, T. Yoshida, T. Sakakura, L.J. Old and Y. Obata, Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality, Proc Natl Acad Sci USA 96 (1999), 29942999.
  • 33
    S. Fujioka, C. Schmidt, G.M. Sclabas, Z. Li, H. Pelicano, B. Peng, A. Yao, J. Niu, W. Zhang, D.B. Evans, J.L. Abbruzzese, P. Huang and P.J. Chiao, Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB, J Biol Chem 279 (2004), 2754927559.
  • 34
    A.J. Garcia-Pineres, M.T. Lindenmeyer and I. Merfort, Role of cysteine residues of p65/NF-kappaB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential, Life Sci 75 (2004), 841856.
  • 35
    A. Garg and B.B. Aggarwal, Nuclear transcription factor-kappaB as a target for cancer drug development, Leukemia 16 (2002), 10531068.
  • 36
    S. Ghosh and M. Karin, Missing pieces in the NF-kappaB puzzle, Cell 109 Suppl (2002), S8196.
  • 37
    T.D. Gilmore, Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel, Oncogene 18 (1999), 69256937.
  • 38
    A. Glasmacher, C. Hahn, F. Hoffmann, R. Naumann, H. Goldschmidt, M. von Lilienfeld-Toal, K. Orlopp, I. Schmidt-Wolf and M. Gorschluter, A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma, Br J Haematol 132 (2006), 584593.
  • 39
    D.C. Guttridge, M.W. Mayo, L.V. Madrid, C.Y. Wang and A.S. Baldwin, Jr., NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia, Science 289 (2000), 23632366.
  • 40
    C.M. Hansen, D. Hansen, P.K. Holm, R. Larsson and L. Binderup, Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro, Anticancer Res 20 (2000), 42114220.
  • 41
    E.N. Hatada, A. Nieters, F.G. Wulczyn, M. Naumann, R. Meyer, G. Nucifora, T.W. McKeithan and C. Scheidereit, The ankyrin repeat domains of the NF-kappa B precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding, Proc Natl Acad Sci USA 89 (1992), 24892493.
  • 42
    J.M. Herendeen and C. Lindley, Use of NSAIDs for the chemoprevention of colorectal cancer, Ann Pharmacother 37 (2003), 16641674.
  • 43
    K.A. Higgins, J.R. Perez, T.A. Coleman, K. Dorshkind, W.A. McComas, U.M. Sarmiento, C.A. Rosen and R. Narayanan, Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression, Proc Natl Acad Sci USA 90 (1993), 99019905.
  • 44
    M. Hinz, P. Loser, S. Mathas, D. Krappmann, B. Dorken and C. Scheidereit, Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed- Sternberg cells, Blood 97 (2001), 27982807.
  • 45
    P.J. Hjarnaa, E. Jonsson, S. Latini, S. Dhar, R. Larsson, E. Bramm, T. Skov and L. Binderup, CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo, Cancer Res 59 (1999), 57515757.
  • 46
    M. Holmes-McNary and A.S. Baldwin Jr., Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase, Cancer Res 60 (2000), 34773483.
  • 47
    J. Houldsworth, S. Mathew, P.H. Rao, K. Dyomina, D.C. Louie, N. Parsa, K. Offit and R.S. Chaganti, REL proto- oncogene is frequently amplified in extranodal diffuse large cell lymphoma, Blood 87 (1996), 2529.
  • 48
    P. Hovstadius, R. Larsson, E. Jonsson, T. Skov, A.M. Kissmeyer, K. Krasilnikoff, J. Bergh, M.O. Karlsson, A. Lonnebo and J. Ahlgren, A Phase I study of CHS 828 in patients with solid tumor malignancy, Clin Cancer Res 8 (2002), 28432850.
  • 49
    P. Hovstadius, E. Lindhagen, S. Hassan, K. Nilsson, H. Jernberg-Wiklund, P. Nygren, L. Binderup and R. Larsson, Cytotoxic effect in vivoand in vitro of CHS 828 on human myeloma cell lines, Anticancer Drugs 15 (2004), 6370.
  • 50
    C.Y. Hsia, S. Cheng, A.M. Owyang, S.F. Dowdy and H.C. Liou, c-Rel regulation of the cell cycle in primary mouse B lymphocytes, Int Immunol 14 (2002), 905916.
  • 51
    S. Huang, A. DeGuzman, C.D. Bucana and I.J. Fidler, Nuclear factor-kappaB activity correlates with growth, angio- genesis, and metastasis of human melanoma cells in nude mice, Clin Cancer Res 6 (2000), 25732581.
  • 52
    S. Huang, C.A. Pettaway, H. Uehara, C.D. Bucana and I.J. Fidler, Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis, Oncogene 20 (2001), 41884197.
  • 53
    Y. Huang, K.R. Johnson, J.S. Norris and W. Fan, Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells, Cancer Res 60 (2000), 44264432.
  • 54
    S. Hwang and A. Ding, Activation of NF-kappa B in murine macrophages by taxol, Cancer Biochem Biophys 14 (1995), 265272.
  • 55
    V. Imbert, R.A. Rupec, A. Livolsi, H.L. Pahl, E.B. Traenckner, C. Mueller-Dieckmann, D. Farahifar, B. Rossi, P. Auberger, P.A. Baeuerle and J.F. Peyron, Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha, Cell 86 (1996), 787798.
  • 56
    M. Jang, L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W. Beecher, H.H. Fong, N.R. Farnsworth, A.D. Kinghorn, R.G. Mehta, R.C. Moon and J.M. Pezzuto, Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, Science 275 (1997), 218220.
  • 57
    H. Jo, R. Zhang, H. Zhang, T.A. McKinsey, J. Shao, R.D. Beauchamp, D.W. Ballard and P. Liang, NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis, Oncogene 19 (2000), 841849.
  • 58
    C. Jobin, A. Panja, C. Hellerbrand, Y. Iimuro, J. Didonato, D.A. Brenner and R.B. Sartor, Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells, J Immunol 160 (1998), 410418.
  • 59
    V. Johanson, Y. Arvidsson, L. Kolby, P. Bernhardt, C. Sward, O. Nilsson and H. Ahlman, Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice, Neuroendocrinology 82 (2005), 171176.
  • 60
    J.P. Johnson, Cell adhesion molecules in the development and progression of malignant melanoma, Cancer Metastasis Rev 18 (1999), 345357.
  • 61
    D.R. Jones, R.M. Broad, L.V. Madrid, A.S. Baldwin, Jr. and M.W. Mayo, Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis, Ann Thorac Surg 70 (2000), 930936; discussion 936–937.
  • 62
    S. Joos, M.I. Otano-Joos, S. Ziegler, S. Bruderlein, S. du Manoir, M. Bentz, P. Moller and P. Lichter, Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene, Blood 87 (1996), 15711578.
  • 63
    B. Kaltschmidt, C. Kaltschmidt, T.G. Hofmann, S.P. Hehner, W. Droge and M.L. Schmitz, The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus, Eur J Biochem 267 (2000), 38283835.
  • 64
    P. Kapahi, T. Takahashi, G. Natoli, S.R. Adams, Y. Chen, R.Y. Tsien and M. Karin, Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase, J Biol Chem 275 (2000), 3606236066.
  • 65
    M. Karin, Y. Cao, F.R. Greten and Z.W. Li, NF-kappaB in cancer: from innocent bystander to major culprit, Nat Rev Cancer 2 (2002), 301310.
  • 66
    M. Karin and A. Lin, NF-kappaB at the crossroads of life and death, Nat Immunol 3 (2002), 221227.
  • 67
    D. Karunagaran, R. Rashmi and T.R. Kumar, Induction of apoptosis by curcumin and its implications for cancer therapy, Curr Cancer Drug Targets 5 (2005), 117129.
  • 68
    T. Kato, Jr., M. Delhase, A. Hoffmann and M. Karin, CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response, Mol Cell 12 (2003), 829839.
  • 69
    I. Kawamura, R. Morishita, N. Tomita, E. Lacey, M. Aketa, S. Tsujimoto, T. Manda, M. Tomoi, I. Kida, J. Higaki, Y. Kaneda, K. Shimomura and T. Ogihara, Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model, Gene Ther 6 (1999), 9197.
  • 70
    I. Kawamura, R. Morishita, S. Tsujimoto, T. Manda, M. Tomoi, N. Tomita, T. Goto, T. Ogihara and Y. Kaneda, Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice, Gene Ther 8 (2001), 905912.
  • 71
    H.J. Kim, N. Hawke and A.S. Baldwin, NF-kappaB and IKK as therapeutic targets in cancer, Cell Death Differ 13 (2006), 738747.
  • 72
    M. Kimura, M. Haisa, H. Uetsuka, M. Takaoka, T. Ohkawa, R. Kawashima, T. Yamatsuji, M. Gunduz, Y. Kane- da, N. Tanaka and Y. Naomoto, TNF combined with IFN-alpha accelerates NF-kappaB-mediated apoptosis through enhancement of Fas expression in colon cancer cells, Cell Death Differ 10 (2003), 718728.
  • 73
    N. Kishore, C. Sommers, S. Mathialagan, J. Guzova, M. Yao, S. Hauser, K. Huynh, S. Bonar, C. Mielke, L. Albee, R. Weier, M. Graneto, C. Hanau, T. Perry and C.S. Tripp, A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts, J Biol Chem 278 (2003), 3286132871.
  • 74
    S. Kreuz, D. Siegmund, P. Scheurich and H. Wajant, NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling, Mol Cell Biol 21 (2001), 39643973.
  • 75
    J. Kucharczak, M.J. Simmons, Y. Fan and C. Gelinas, To be, or not to be: NF-kappaB is the answer-role of Rel/NF- kappaB in the regulation of apoptosis, Oncogene 22 (2003), 89618982.
  • 76
    S. Kumar and S.V. Rajkumar, Thalidomide and dexamethasone: therapy for multiple myeloma, Expert Rev Anticancer Ther 5 (2005), 759766.
  • 77
    B.H. Kwok, B. Koh, M.I. Ndubuisi, M. Elofsson and C.M. Crews, The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase, Chem Biol 8 (2001), 759766.
  • 78
    F.A. La Rosa, J.W. Pierce and G.E. Sonenshein, Differential regulation of the c-myc oncogene promoter by the NF-kappa B rel family of transcription factors, Mol Cell Biol 14 (1994), 10391044.
  • 79
    A. Ledeboer, M. Gamanos, W. Lai, D. Martin, S.F. Maier, L.R. Watkins and N. Quan, Involvement of spinal cord nuclear factor kappaB activation in rat models of proinflammatory cytokine-mediated pain facilitation, Eur J Neurosci 22 (2005), 19771986.
  • 80
    S. Lev-Ari, Y. Maimon, L. Strier, D. Kazanov and N. Arber, Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines, J Soc Integr Oncol 4 (2006), 2126.
  • 81
    J. Li, D.J. Minnich, E.R. Camp, A. Brank, S.L. Mackay and S.N. Hochwald, Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB, J Surg Res 132 (2006), 112120.
  • 82
    Z.W. Li, W. Chu, Y. Hu, M. Delhase, T. Deerinck, M. Ellisman, R. Johnson and M. Karin, The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis, J Exp Med 189 (1999), 18391845.
  • 83
    R. Lin, P. Beauparlant, C. Makris, S. Meloche and J. Hiscott, Phosphorylation of IkappaBalpha in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability, Mol Cell Biol 16 (1996), 14011409.
  • 84
    Y.Z. Lin, S.Y. Yao, R.A. Veach, T.R. Torgerson and J. Hawiger, Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence, J Biol Chem 270 (1995), 1425514258.
  • 85
    D. Liu, X.Y. Liu, D. Robinson, C. Burnett, C. Jackson, L. Seele, R.A. Veach, S. Downs, R.D. Collins, D.W. Ballard and J. Hawiger, Suppression of Staphylococcal Enterotoxin B-induced Toxicity by a Nuclear Import Inhibitor, J Biol Chem 279 (2004), 1923919246.
  • 86
    T. Loch, B. Michalski, U. Mazurek and M. Graniczka, Vascular endothelial growth factor (VEGF) and its role in neoplastic processes, Postepy Hig Med Dosw 55 (2001), 257274.
  • 87
    Y. Lu, L. Jamieson, A.R. Brasier and A.P. Fields, NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival, Oncogene 20 (2001), 47774792.
  • 88
    Y.S. Lu, H.C. Lien, P.Y. Yeh, K.H. Yeh, M.L. Kuo, S.H. Kuo and A.L. Cheng, Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors, World J Gastroenterol 11 (2005), 63736380.
  • 89
    Y.S. Lu, P.Y. Yeh, S.E. Chuang, M. Gao, M.L. Kuo and A.L. Cheng, Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa, J Endocrinol 188 (2006), 311319.
  • 90
    J.L. Luo, H. Kamata and M. Karin, IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy, J Clin Invest 115 (2005), 26252632.
  • 91
    M.J. May, F. D'Acquisto, L.A. Madge, J. Glockner, J.S. Pober and S. Ghosh, Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex, Science 289 (2000), 15501554.
  • 92
    M.J. May, R.B. Marienfeld and S. Ghosh, Characterization of the Ikappa B-kinase NEMO binding domain, J Biol Chem 277 (2002), 4599246000.
  • 93
    L.I. McKay and J.A. Cidlowski, Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mecha- nisms of mutual antagonism, Mol Endocrinol 12 (1998), 4556.
  • 94
    L.I. McKay and J.A. Cidlowski, Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways, Endocr Rev 20 (1999), 435459.
  • 95
    A. Migliazza, L. Lombardi, M. Rocchi, D. Trecca, C.C. Chang, R. Antonacci, N.S. Fracchiolla, P. Ciana, A.T. Maiolo and A. Neri, Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies, Blood 84 (1994), 38503860.
  • 96
    J.F. Milligan, M.D. Matteucci and J.C. Martin, Current concepts in antisense drug design, J Med Chem 36 (1993), 19231937.
  • 97
    U. Naumann, S. Durka and M. Weller, Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?., Oncogene 17 (1998), 15671575.
  • 98
    A. Neri, N.S. Fracchiolla, E. Roscetti, S. Garatti, D. Trecca, A. Boletini, L. Perletti, L. Baldini, A.T. Maiolo and E. Berti, Molecular analysis of cutaneous B- and T-cell lymphomas, Blood 86 (1995), 31603172.
  • 99
    D.M. Nguyen, G.A. Chen, R. Reddy, W. Tsai, W.D. Schrump, G. Cole, Jr. and D.S. Schrump, Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway, J Thorac Cardiovasc Surg 127 (2004), 365375.
  • 100
    U. Novak, B.G. Cocks and J.A. Hamilton, A labile repressor acts through the NFkB-like binding sites of the human urokinase gene, Nucleic Acids Res 19 (1991), 33893393.
  • 101
    L.S. Olsen, P.J. Hjarnaa, S. Latini, P.K. Holm, R. Larsson, E. Bramm, L. Binderup and M.W. Madsen, Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity, Int J Cancer 111 (2004), 198205.
  • 102
    H.L. Pahl, Activators and target genes of Rel/NF-kappaB transcription factors, Oncogene 18 (1999), 68536866.
  • 103
    M.S. Palanki, L.M. Gayo-Fung, G.I. Shevlin, P. Erdman, M. Sato, M. Goldman, L.J. Ransone and C. Spooner, Structure- activity relationship studies of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine- 5- carboxylate: an inhibitor of AP-1 and NF-kappaB mediated gene expression, Bioorg Med Chem Lett 12 (2002), 25732577.
  • 104
    N.M. Patel, S. Nozaki, N.H. Shortle, P. Bhat-Nakshatri, T.R. Newton, S. Rice, V. Gelfanov, S.H. Boswell, R.J. Goulet, Jr., G.W. Sledge, Jr. and H. Nakshatri, Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide, Oncogene 19 (2000), 41594169.
  • 105
    N.D. Perkins, Regulation of NF-kappaB by atypical activators and tumour suppressors, Biochem Soc Trans 32 (2004), 936939.
  • 106
    G.M. Pieper and H. Riaz ul, Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C, J Cardiovasc Pharmacol 30 (1997), 528532.
  • 107
    E. Pikarsky and Y. Ben-Neriah, NF-kappaB inhibition: a double-edged sword in cancer?., Eur J Cancer 42 (2006), 779784.
  • 108
    R. Piva, P. Gianferretti, A. Ciucci, R. Taulli, G. Belardo and M.G. Santoro, 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins, Blood 105 (2005), 17501758.
  • 109
    H. Rangaswami, A. Bulbule and G.C. Kundu, Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation, J Biol Chem 279 (2004), 3892138935.
  • 110
    A. Ravaud, T. Cerny, C. Terret, J. Wanders, B.N. Bui, D. Hess, J.P. Droz, P. Fumoleau and C. Twelves, Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study, Eur J Cancer 41 (2005), 702707.
  • 111
    R. Ravi and A. Bedi, NF-kappaB in cancer-a friend turned foe, Drug Resist Updat 7 (2004), 5367.
  • 112
    R. Ravi, G.C. Bedi, L.W. Engstrom, Q. Zeng, B. Mookerjee, C. Gelinas, E.J. Fuchs and A. Bedi, Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB, Nat Cell Biol 3 (2001), 409416.
  • 113
    B. Rayet and C. Gelinas, Aberrant rel/nfkb genes and activity in human cancer, Oncogene 18 (1999), 69386947.
  • 114
    J.Y. Reuther, G.W. Reuther, D. Cortez, A.M. Pendergast and A.S. Baldwin, Jr., A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation, Genes Dev 12 (1998), 968981.
  • 115
    P.G. Richardson, T. Hideshima, C. Mitsiades and K. Anderson, Proteasome inhibition in hematologic malignancies, Ann Med 36 (2004), 304314.
  • 116
    P.G. Richardson, C. Mitsiades, T. Hideshima and K.C. Anderson, Bortezomib: proteasome inhibition as an effective anticancer therapy, Annu Rev Med 57 (2006), 3347.
  • 117
    P.A. Robe, M. Bentires-Alj, M. Bonif, B. Rogister, M. Deprez, H. Haddada, M.T. Khac, O. Jolois, K. Erkmen, M.P. Merville, P.M. Black and V. Bours, In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas, Clin Cancer Res 10 (2004), 55955603.
  • 118
    M. Roberti, D. Pizzirani, D. Simoni, R. Rondanin, R. Baruchello, C. Bonora, F. Buscemi, S. Grimaudo and M. Tolomeo, Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents, J Med Chem 46 (2003), 35463554.
  • 119
    M.T. Rojewski, S. Korper and H. Schrezenmeier, Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside, Leuk Lymphoma 45 (2004), 23872401.
  • 120
    J.J. Ross, J.T. Arnason and H.C. Birnboim, Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion, Planta Med 65 (1999), 126129.
  • 121
    A. Rossi, P. Kapahi, G. Natoli, T. Takahashi, Y. Chen, M. Karin and M.G. Santoro, Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase, Nature 403 (2000), 103108.
  • 122
    D. Rudolph, W.C. Yeh, A. Wakeham, B. Rudolph, D. Nallainathan, J. Potter, A.J. Elia and T.W. Mak, Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice, Genes Dev 14 (2000), 854862.
  • 123
    K.M. Ryan, M.K. Ernst, N.R. Rice and K.H. Vousden, Role of NF-kappaB in p53-mediated programmed cell death, Nature 404 (2000), 892897.
  • 124
    M.G. Santoro, A. Crisari, A. Benedetto and C. Amici, Modulation of the growth of a human erythroleukemic cell line (K562) by prostaglandins: antiproliferative action of prostaglandin A, Cancer Res 46 (1986), 60736077.
  • 125
    T. Sato, H. Odagiri, S.K. Ikenaga, M. Maruyama and M. Sasaki, Chemosensitivity of human pancreatic carcinoma cells is enhanced by IkappaBalpha super-repressor, Cancer Sci 94 (2003), 467472.
  • 126
    C.L. Scaife, J. Kuang, J.C. Wills, D.B. Trowbridge, P. Gray, B.M. Manning, E.J. Eichwald, R.A. Daynes and S.K. Kuwa- da, Nuclear factor kappaB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis, Cancer Res 62 (2002), 68706878.
  • 127
    R. Schreck, B. Meier, D.N. Mannel, W. Droge and P.A. Baeuerle, Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells, J Exp Med 175 (1992), 11811194.
  • 128
    R. Sen and D. Baltimore, Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttrans- lational mechanism, Cell 47 (1986), 921928.
  • 129
    U. Senftleben, Y. Cao, G. Xiao, F.R. Greten, G. Krahn, G. Bonizzi, Y. Chen, Y. Hu, A. Fong, S.C. Sun and M. Karin, Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway, Science 293 (2001), 14951499.
  • 130
    U. Senftleben and M. Karin, The IKK/NF-kappa B pathway, Crit Care Med 30 (2002), S1826.
  • 131
    U. Senftleben, Z.W. Li, V. Baud and M. Karin, IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis, Immunity 14 (2001), 217230.
  • 132
    R. Shao, D. Karunagaran, B.P. Zhou, K. Li, S.S. Lo, J. Deng, P. Chiao and M.C. Hung, Inhibition of nuclear factor- kappaB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis, J Biol Chem 272 (1997), 3273932742.
  • 133
    H.W. Sharma and R. Narayanan, The NF-kappaB transcription factor in oncogenesis, Anticancer Res 16 (1996), 589596.
  • 134
    A.M. Sheehy and M.S. Schlissel, Overexpression of RelA causes G1 arrest and apoptosis in a pro-B cell line, J Biol Chem 274 (1999), 87088716.
  • 135
    S. Shishodia, D. Koul and B.B. Aggarwal, Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF- kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis, J Immunol 173 (2004), 20112022.
  • 136
    S. Shoji, K. Furuishi, A. Ogata, K. Yamataka, K. Tachibana, R. Mukai, A. Uda, K. Harano, S. Matsushita and S. Misumi, An allosteric drug, o,o'-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-kappa B, Biochem Biophys Res Commun 249 (1998), 745753.
  • 137
    U. Siebenlist, G. Franzoso and K. Brown, Structure, regulation and function of NF-kappa B, Annu Rev Cell Biol 10 (1994), 405455.
  • 138
    S. Singh and A. Khar, Biological effects of curcumin and its role in cancer chemoprevention and therapy, Anticancer Agents Med Chem 6 (2006), 259270.
  • 139
    S.L. Soignet, S.R. Frankel, D. Douer, M.S. Tallman, H. Kantarjian, E. Calleja, R.M. Stone, M. Kalaycio, D.A. Scheinberg, P. Steinherz, E.L. Sievers, S. Coutre, S. Dahlberg, R. Ellison and R.P. Warrell, Jr., United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia, J Clin Oncol 19 (2001), 38523860.
  • 140
    A. Stoffel and A.J. Levine, Actvation of NF-kappaB by the API2/MALT1 fusions inhibits p53 dependant but not FAS induced apoptosis: a directional link between NF-kappaB and p53, Cell Cycle 3 (2004), 10171020.
  • 141
    D.S. Straus and C.K. Glass, Cyclopentenone prostaglandins: new insights on biological activities and cellular targets, Med Res Rev 21 (2001), 185210.
  • 142
    C.J. Sweeney, S. Mehrotra, M.R. Sadaria, S. Kumar, N.H. Shortle, Y. Roman, C. Sheridan, R.A. Campbell, D.J. Murry, S. Badve and H. Nakshatri, The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer, Mol Cancer Ther 4 (2005), 10041012.
  • 143
    Y. Takada, A. Bhardwaj, P. Potdar and B.B. Aggarwal, Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation, Oncogene 23 (2004), 92479258.
  • 144
    V. Tarabin and M. Schwaninger, The role of NF-kappaB in 6-hydroxydopamine- and TNFalpha-induced apoptosis of PC12 cells, Naunyn Schmiedebergs Arch Pharmacol 369 (2004), 563569.
  • 145
    S.K. Teo, D.I. Stirling and J.B. Zeldis, Thalidomide as a novel therapeutic agent: new uses for an old product, Drug Discov Today 10 (2005), 107114.
  • 146
    V. Tergaonkar, M. Pando, O. Vafa, G. Wahl and I. Verma, p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy, Cancer Cell 1 (2002), 493503.
  • 147
    M. Tsujii, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori and R.N. DuBois, Cyclooxygenase regulates angiogenesis induced by colon cancer cells, Cell 93 (1998), 705716.
  • 148
    M.C. Turco, M.F. Romano, A. Petrella, R. Bisogni, P. Tassone and S. Venuta, NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors, Leukemia 18 (2004), 1117.
  • 149
    H. Uetsuka, M. Haisa, M. Kimura, M. Gunduz, Y. Kaneda, T. Ohkawa, M. Takaoka, T. Murata, T. Nobuhisa, T. Yamatsuji, J. Matsuoka, N. Tanaka and Y. Naomoto, Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5- fluorouracil in human stomach cancer cell line, Exp Cell Res 289 (2003), 2735.
  • 150
    D.J. Van Antwerp and I.M. Verma, Signal-induced degradation of I(kappa)B(alpha): association with NF-kappaB and the PEST sequence in I(kappa)B(alpha) are not required, Mol Cell Biol 16 (1996), 60376045.
  • 151
    C.Y. Wang, J.C. Cusack, Jr., R. Liu and A.S. Baldwin, Jr., Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB, Nat Med 5 (1999), 412417.
  • 152
    C.Y. Wang, M.W. Mayo and A.S. Baldwin, Jr., TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB, Science 274 (1996), 784787.
  • 153
    Y. Wang, H. Cui, A. Schroering, J.L. Ding, W.S. Lane, G. McGill, D.E. Fisher and H.F. Ding, NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function, Nat Cell Biol 4 (2002), 888893.
  • 154
    Z. Wang, Y. Zhang, S. Banerjee, Y. Li and F.H. Sarkar, Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells, Cancer 106 (2006), 25032513.
  • 155
    J. Wen, K.R. You, S.Y. Lee, C.H. Song and D.G. Kim, Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide, J Biol Chem 277 (2002), 3895438964.
  • 156
    Z. Wiener, E.C. Ontsouka, S. Jakob, R. Torgler, A. Falus, C. Mueller and T. Brunner, Synergistic induction of the Fas (CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells, Exp Cell Res 299 (2004), 227235.
  • 157
    Y.K. Won, C.N. Ong, X. Shi and H.M. Shen, Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms, Carcinogenesis 25 (2004), 14491458.
  • 158
    C. Wu, F. Chen, J.W. Rushing, X. Wang, H.J. Kim, G. Huang, V. Haley-Zitlin and G. He, Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines, J Med Food 9 (2006), 5561.
  • 159
    W. Wu, T. Pew, M. Zou, D. Pang and S.D. Conzen, Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival, J Biol Chem 280 (2005), 41174124.
  • 160
    G. Xiao, E.W. Harhaj and S.C. Sun, NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100, Mol Cell 7 (2001), 401409.
  • 161
    N. Yamagishi, J. Miyakoshi and H. Takebe, Enhanced radiosensitivity by inhibition of nuclear factor kappa B activation in human malignant glioma cells, Int J Radiat Biol 72 (1997), 157162.
  • 162
    Y. Yamamoto, M.J. Yin, K.M. Lin and R.B. Gaynor, Sulindac inhibits activation of the NF-kappaB pathway, J Biol Chem 274 (1999), 2730727314.
  • 163
    S. Yamaoka, H. Inoue, M. Sakurai, T. Sugiyama, M. Hazama, T. Yamada and M. Hatanaka, Constitutive activation of NF-kappa B is essential for transformation of rat fibroblasts by the human T-cell leukemia virus type I Tax protein, Embo J 15 (1996), 873887.
  • 164
    A. Yemelyanov, A. Gasparian, P. Lindholm, L. Dang, J.W. Pierce, F. Kisseljov, A. Karseladze and I. Budunova, Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells, Oncogene 25 (2006), 387398.
  • 165
    D. Yin, H. Zhou, T. Kumagai, G. Liu, J.M. Ong, K.L. Black and H.P. Koeffler, Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM), Oncogene 24 (2005), 344354.
  • 166
    Y.Y. Yu, Q. Li and Z.G. Zhu, NF-kappaB as a molecular target in adjuvant therapy of gastrointestinal carcinomas, Eur J Surg Oncol 31 (2005), 386392.
  • 167
    S. Zhang, C.N. Ong and H.M. Shen, Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells, Cancer Lett 208 (2004), 143153.
  • 168
    S. Zhang, C.N. Ong and H.M. Shen, Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis, Cancer Lett 211 (2004), 175188.
  • 169
    L.D. Zheng, Q.S. Tong and C.H. Wu, Growth inhibition and apoptosis inducing mechanisms of curcumin on human ovarian cancer cell line a2780, Chin J Integr Med 12 (2006), 126131.